Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199396 | 0.87 | ALDH1A1 (0.47) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL22007930 | 0.87 | BAZ2B (0.43) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL22350326 | 0.85 | BAZ2B (0.40) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL16236608 | 0.85 | BAZ2B (0.40) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL22821250 | 0.78 | BAZ2B (0.43) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL22007929 | 0.77 | CA1 (0.48) | KMT2ABAZ2BBAZ2AALDH1A1HPGD | |
| SCHEMBL21707947 | 0.76 | PDK1 (0.40) | KMT2AALDH1A1GAAMAPTHPGD | |
| SCHEMBL6779742 | 0.76 | BAZ2B (0.54) | KMT2ABAZ2BBAZ2AALDH1A1USP2 | |
| SCHEMBL17700812 | 0.75 | KMT2A (0.39) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 | |
| SCHEMBL21700027 | 0.75 | MAPT (0.40) | KMT2ABAZ2BBAZ2AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601788-B | Capsid protein assembly inhibitor, pharmaceutical composition and use thereof | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-111601788-A | Capsid protein assembly inhibitor, pharmaceutical composition and use thereof | 正大天晴药业集团股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-29 | — | — | US | disclosed |
| WO-2019154343-A1 | CAPSID PROTEIN ASSEMBLY INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154343-A1 | CAPSID PROTEIN ASSEMBLY INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2019-08-15 | — | — | WO | disclosed |
| EP-2997011-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-24 | — | — | US | disclosed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| EP-3121164-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| EP-2997011-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184350-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885BAZ2B 130/4885BAZ2A 96/4885 |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, XDH, HBS1L | KMT2A 1220/4885BAZ2B 130/4885BAZ2A 96/4885 |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885BAZ2B 130/4885BAZ2A 96/4885 |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885BAZ2B 130/4885BAZ2A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.